South Korea Atopic Dermatitis Drugs Market Size & Outlook
South Korea atopic dermatitis drugs market, 2017-2028 (US$M)
Related Markets
South Korea atopic dermatitis drugs market highlights
- The South Korea atopic dermatitis drugs market generated a revenue of USD 141.3 million in 2020 and is expected to reach USD 499.3 million by 2028.
- The South Korea market is expected to grow at a CAGR of 17.1% from 2021 to 2028.
- In terms of segment, oral was the largest revenue generating administration in 2020.
- Injectable is the most lucrative administration segment registering the fastest growth during the forecast period.
Atopic dermatitis drugs market data book summary
| Market revenue in 2020 | USD 141.3 million |
| Market revenue in 2028 | USD 499.3 million |
| Growth rate | 17.1% (CAGR from 2020 to 2028) |
| Largest segment | Oral |
| Fastest growing segment | Injectable |
| Historical data | 2017 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Topical, Injectable, Oral |
| Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.3% of the global atopic dermatitis drugs market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In Asia Pacific, Japan atopic dermatitis drugs market is projected to lead the regional market in terms of revenue in 2028.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 819.3 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Atopic Dermatitis Drugs Market Scope
Atopic Dermatitis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Korea atopic dermatitis drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Oral was the largest segment with a revenue share of 44.37% in 2020. Horizon Databook has segmented the South Korea atopic dermatitis drugs market based on topical, injectable, oral covering the revenue growth of each sub-segment from 2017 to 2028.
Increasing awareness among people and local presence of prominent players are projected to drive the market in South Korea. In addition, increasing incidence of atopic dermatitis is expected to act as a driver. Increase in geriatric population is also likely to significantly contribute to market growth in South Korea.
Growing geriatric population is expected to significantly contribute to market growth in South Korea. South Korea’s elderly population comprises 15.6% of residents that are highly susceptible to atopic dermatitis. In addition, the country’s National Health Insurance covers the total population.
Such favorable government initiatives are key contributors to market growth. In August 2018, LEO Pharma announced the acquisition of JW1601 from JW Pharma, which is an early-stage atopic dermatitis drug for marketing and development, for USD 17 million.
Reasons to subscribe to South Korea atopic dermatitis drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Korea atopic dermatitis drugs market databook
-
Our clientele includes a mix of atopic dermatitis drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into South Korea atopic dermatitis drugs market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
South Korea atopic dermatitis drugs market size, by administration, 2017-2028 (US$M)
South Korea Atopic Dermatitis Drugs Market Outlook Share, 2020 & 2028 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
